# China NMPA Drug Inspection - 17 companies including Hebei Kangyiqiang Pharmaceutical Co., Ltd. - 19 batches of Chinese herbal medicine slices

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/17-companies-including-hebei-kangyiqiang-pharmaceutical-co-ltd/80da2013-c107-4fe9-a5ed-52bb1549d7bf/
Source feed: China

> China NMPA drug inspection for 17 companies including Hebei Kangyiqiang Pharmaceutical Co., Ltd. published November 18, 2019. Drug: 19 batches of Chinese herbal medicine slices. The Shandong Provincial Food and Drug Administration, under the National Medical Products Administration (NMPA), issued 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from Shandong Provincial Food and Drug Administration Regarding 20 Batches of Drugs Failing Quality Inspection (No. 10, 2018)
- Company Name: 17 companies including Hebei Kangyiqiang Pharmaceutical Co., Ltd.
- Publication Date: 2019-11-18
- Drug Name: 19 batches of Chinese herbal medicine slices
- Inspection Finding: The quality of the sampled product did not meet the standard requirements.
- Action Taken: The relevant municipal food and drug administrations have taken control measures such as sealing, seizing, suspending sales, and recalling the substandard products. They have also initiated investigations or are currently investigating the relevant manufacturers and sampled units in accordance with relevant laws and regulations. The relevant municipal food and drug administrations should strengthen supervision of the substandard products and the corresponding enterprises and units, urging them to investigate the causes of the problems, formulate and implement rectification measures, and effectively eliminate potential risks.
- Summary: The Shandong Provincial Food and Drug Administration, under the National Medical Products Administration (NMPA), issued Announcement No. 128 on October 10, 2018 (published November 18, 2019), detailing the outcomes of a comprehensive drug quality inspection. Inspections, carried out by nine drug testing institutions including the Shandong Provincial Institute for Food and Drug Control, identified 20 batches of pharmaceutical products failing to meet established quality standards. Specifically, one batch of drugs from Jiangsu Dahongying Hengshun Pharmaceutical Co., Ltd., and 19 batches of traditional Chinese medicine decoction pieces from 17 companies, including Hebei Kangyiqiang Pharmaceutical Co., Ltd., were deemed substandard. While specific deviations were not detailed, the findings highlighted critical quality non-compliance. In response, municipal food and drug administrations have taken immediate control actions, including sealing, seizing, suspending sales, and recalling the affected products. Investigations have been initiated against the responsible manufacturers and sampled units under relevant drug regulatory laws. Furthermore, enterprises are mandated to thoroughly investigate the root causes of these quality deficiencies and implement corrective measures to effectively mitigate potential risks, with ongoing intensified supervision from regulatory bodies.

Company: https://www.globalkeysolutions.net/companies/17-companies-including-hebei-kangyiqiang-pharmaceutical-co-ltd/f07f1ce7-c765-4dd9-912f-85418bfa3514/